These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 33794182)

  • 21. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial).
    Slama L; Landman R; Assoumou L; Benalycherif A; Samri A; Joly V; Pialoux G; Valin N; Cabié A; Duvivier C; Lambert-Niclot S; Marcelin AG; Peytavin G; Costagliola D; Girard PM;
    J Antimicrob Chemother; 2016 Aug; 71(8):2252-61. PubMed ID: 27068399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial.
    Molina JM; Squires K; Sax PE; Cahn P; Lombaard J; DeJesus E; Lai MT; Xu X; Rodgers A; Lupinacci L; Kumar S; Sklar P; Nguyen BY; Hanna GJ; Hwang C;
    Lancet HIV; 2018 May; 5(5):e211-e220. PubMed ID: 29592840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
    Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
    J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epigenetic aging in older people living with HIV in Eswatini: a pilot study of HIV and lifestyle factors and epigenetic aging.
    Dye CK; Wu H; Jackson GL; Kidane A; Nkambule R; Lukhele NG; Malinga BP; Chekenyere R; El-Sadr WM; Baccarelli AA; Harris TG
    Clin Epigenetics; 2024 Feb; 16(1):32. PubMed ID: 38403593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose ritonavir-boosted darunavir once daily versus ritonavir-boosted lopinavir for participants with less than 50 HIV RNA copies per mL (WRHI 052): a randomised, open-label, phase 3, non-inferiority trial.
    Venter WDF; Moorhouse M; Sokhela S; Serenata C; Akpomiemie G; Qavi A; Mashabane N; Arulappan N; Sim JW; Sinxadi PZ; Wiesner L; Maharaj E; Wallis C; Boyles T; Ripin D; Stacey S; Chitauri G; Hill A
    Lancet HIV; 2019 Jul; 6(7):e428-e437. PubMed ID: 31202690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study.
    Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY;
    Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Accelerated Epigenetic Aging in Peripheral Blood does not Predict Dementia Risk.
    Fransquet PD; Lacaze P; Saffery R; Shah RC; Vryer R; Murray A; Woods RL; Ryan J
    Curr Alzheimer Res; 2021; 18(5):443-451. PubMed ID: 34429046
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic Age and the Risk of Incident Atrial Fibrillation.
    Roberts JD; Vittinghoff E; Lu AT; Alonso A; Wang B; Sitlani CM; Mohammadi-Shemirani P; Fornage M; Kornej J; Brody JA; Arking DE; Lin H; Heckbert SR; Prokic I; Ghanbari M; Skanes AC; Bartz TM; Perez MV; Taylor KD; Lubitz SA; Ellinor PT; Lunetta KL; Pankow JS; Paré G; Sotoodehnia N; Benjamin EJ; Horvath S; Marcus GM
    Circulation; 2021 Dec; 144(24):1899-1911. PubMed ID: 34587750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A meta-analysis of genome-wide association studies of epigenetic age acceleration.
    Gibson J; Russ TC; Clarke TK; Howard DM; Hillary RF; Evans KL; Walker RM; Bermingham ML; Morris SW; Campbell A; Hayward C; Murray AD; Porteous DJ; Horvath S; Lu AT; McIntosh AM; Whalley HC; Marioni RE
    PLoS Genet; 2019 Nov; 15(11):e1008104. PubMed ID: 31738745
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial.
    Kunisaki KM; Niewoehner DE; Collins G; Aagaard B; Atako NB; Bakowska E; Clarke A; Corbelli GM; Ekong E; Emery S; Finley EB; Florence E; Infante RM; Kityo CM; Madero JS; Nixon DE; Tedaldi E; Vestbo J; Wood R; Connett JE;
    Lancet Respir Med; 2016 Dec; 4(12):980-989. PubMed ID: 27773665
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.
    O'Connor J; Vjecha MJ; Phillips AN; Angus B; Cooper D; Grinsztejn B; Lopardo G; Das S; Wood R; Wilkin A; Klinker H; Kantipong P; Klingman KL; Jilich D; Herieka E; Denning E; Abubakar I; Gordin F; Lundgren JD;
    Lancet HIV; 2017 Mar; 4(3):e105-e112. PubMed ID: 28063815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epigenetic Age Acceleration and Hearing: Observations From the Baltimore Longitudinal Study of Aging.
    Kuo PL; Moore AZ; Lin FR; Ferrucci L
    Front Aging Neurosci; 2021; 13():790926. PubMed ID: 34975461
    [No Abstract]   [Full Text] [Related]  

  • 33. Epigenetic Aging Biomarkers Associated With Cognitive Impairment in Older African American Adults With Human Immunodeficiency Virus (HIV).
    Shiau S; Arpadi SM; Shen Y; Cantos A; Ramon CV; Shah J; Jang G; Manly JJ; Brickman AM; Baccarelli AA; Yin MT
    Clin Infect Dis; 2021 Dec; 73(11):1982-1991. PubMed ID: 34143869
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in Cognitive Function Over 96 Weeks in Naive Patients Randomized to Darunavir-Ritonavir Plus Either Raltegravir or Tenofovir-Emtricitabine: A Substudy of the NEAT001/ANRS143 Trial.
    Winston A; Stöhr W; Antinori A; Amieva H; Perré P; De Wit S; Reynes J; Gompels M; dʼArminio Monforte A; Gatell JM; Grarup J; Pozniak A; Babiker A; Raffi F; Richert L;
    J Acquir Immune Defic Syndr; 2017 Feb; 74(2):185-192. PubMed ID: 27749603
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir.
    George EC; Bucciardini R; Richert L; Dedes N; Fragola V; Nieuwkerk P; Spire B; Volny-Anne A; West B; Molina JM; Horban A; Fox J; Pozniak A; Vella S; Termote M; Raffi F;
    J Acquir Immune Defic Syndr; 2018 Dec; 79(4):519-526. PubMed ID: 30234665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of paternal education on epigenetic ageing in adolescence and mid-adulthood: a multi-cohort study in the USA and Mexico.
    Joyce BT; Gao T; Koss K; Zheng Y; Cardenas A; Heiss J; Just A; Zhang K; van Horn L; Allen NB; Greenland P; Cohen S; Gordon-Larsen P; Mitchell C; McLanahan S; Schneper L; Notterman D; Rifas-Shiman SL; Oken E; Hivert MF; Wright R; Baccarelli A; Lloyd-Jones D; Hou L
    Int J Epidemiol; 2022 Jun; 51(3):870-884. PubMed ID: 34534313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Body composition and adipokines changes after initial treatment with darunavir-ritonavir plus either raltegravir or tenofovir disoproxil fumarate-emtricitabine: A substudy of the NEAT001/ANRS143 randomised trial.
    Bernardino JI; Mocroft A; Wallet C; de Wit S; Katlama C; Reiss P; Mallon PW; Richert L; Molina JM; Knobel H; Morlat P; Babiker A; Pozniac A; Raffi F; Arribas JR;
    PLoS One; 2019; 14(1):e0209911. PubMed ID: 30689664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
    Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
    Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
    Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
    Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of walking on epigenetic age acceleration: a Mendelian randomization study.
    Chen GY; Liu C; Xia Y; Wang PX; Zhao ZY; Li AY; Zhou CQ; Xiang C; Zhang JL; Zeng Y; Gu P; Li H
    Clin Epigenetics; 2024 Jul; 16(1):94. PubMed ID: 39026267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.